Synonym
CMP5; CMP-5; CMP 5; CMP5 HCl; CMP5 hydrochloride.
IUPAC/Chemical Name
1-(9-Ethyl-9H-carbazol-3-yl)-N-(2-pyridinylmethyl)methanamine hydrochloride.
InChi Key
LTMOFUKBECEABM-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H21N3.ClH/c1-2-24-20-9-4-3-8-18(20)19-13-16(10-11-21(19)24)14-22-15-17-7-5-6-12-23-17;/h3-13,22H,2,14-15H2,1H3;1H
SMILES Code
CCN1C2=C(C3=C1C=CC=C3)C=C(CNCC4=NC=CC=C4)C=C2.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
PRMT5 is the predominant type II PRMT and in association with the WD-repeat-containing protein MEP50 (methylosome protein 50) forms large multimolecular complexes with different binding partners. PRMT5 is postulated to have a relationship with cell growth, cell cycle progression, cell death, and cell proliferation.
PRMT5 was validated as an anticancer target in mantle cell lymphoma (MCL) and glioblastoma.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
351.88
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Alinari, L.; Mahasenan, K. V.; Yan, F.; Karkhanis, V.; Chung, J. H.; Smith, E. M.; Quinion, C.; Smith, P. L.; Kim, L.; Patton, J. T.; Lapalombella, R.; Yu, B.; Wu, Y.; Roy, S.; De Leo, A.; Pileri, S.; Agostinelli, C.; Ayers, L.; Bradner, J. E.; Chen-Kiang, S.; Elemento, O.; Motiwala, T.; Majumder, S.; Byrd, J. C.; Jacob, S.; Sif, S.; Li, C.; Baiocchi, R. A. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood 2015, 125, 2530−2543.
